Relative bioavailability and pharmacokinetic study of two trimetazidine modified release formulations in healthy Bangladeshi male volunteers

Abstract

Trimetazidine (CAS 5011-34-7) is an effective and well-tolerated antianginal drug that possesses protective properties against ischemia-induced heart injury. The relative bioavailability and pharmacokinetic characteristics of two modified release formulations of 35 mg trimetazidine, one as the test product (Metacard MR) and one as the reference product, were compared in healthy Bangladeshi male volunteers. The randomized, two-way crossover study was conducted in 24 healthy male volunteers after administration of a single 35 mg dose of each modified release formulation after 12-h overnight fasting, with a washout period of two weeks. Blood samples were collected at various time intervals following oral administration and analyzed for trimetazidine concentrations using a validated HPLC method. The pharmacokinetic parameters were determined by a non-compartmental method. After administering a single dose of 35 mg of each trimetazidine formulation, the obtained mean (SD) values for the test and reference products were 104.78 (29.3) and 98.57 (28.7) ng/ml for C_max; 4.00 (1.1) and 3.54 (1.32) h for t_max; 423.81 (173.9) and 410.01 (195.87) ng · h/ml for AUC_0–12; and 472.51 (195.2) and 462.78 (225.13) ng · h/ml for AUC_o–∞ respectively. The mean t_1/2 was found 3.69 (1.1) h and 3.45 (0.72) h for test and reference products respectively. From paired t-test, no significant differences were observed (p > 0.05) for any pharmacokinetic parameters. The 90% confidence intervals of the test/reference mean ratios of the In-transformed AUC_0–12, AUC_0–∞ and C_max mean values were 106.19% (97.16%–116.06%), 104.74% (95.04%–115.42%) and 106.30% (95.23%–118.66%), respectively. The two formulations demonstrated similar bioavailability with respect to both the rate and extent of trimetazidine absorption.

Key words

Anti-anginal drug - Bangladeshi volunteers - Pharmacokinetics - Relative bioavailability - Trimetazidine

• References

• 1 Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8
• 2 Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 893-9
• 3 Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37: 279-88
• 4 Medvedovici A, Albu F, Georgitand C, David V. Non-extractive procedure followed by LC/APCI MS/MS analysis of trimetazidine in plasma samples for assessing bioequivalence of immediate/modified release formulations. Clin Drug Invest 2001; 21 (1) 73-8
• 5 Krishnaiah YSR, Karthikeyan RS, Sankar VG, Satyanarayana V. Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine Dihy-drochloride. J Control Release 2002; 81: 45-56
• 6 Barr’e J, Ledudal P, Oosterhuis B, Brakenhoff JP, Wilkens G, Sollie FA et al. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. Biopharm Drug Dispos 2003; 24: 159-64
• 7 Holban I. Introducing Vastarel MR, the twice-daily 3-KAT inhibitor with sustained antianginal efficacy at trough. Heart Metab 2003; 20: 29-32
• 8 Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3: 361-9
• 9 Génissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet 2004; 29: 61-8
• 10 McClellan KJ, Plosker GL. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999; 58 (1) 143-57
• 11 Jiao Y, Su MM, Chen MJ, Jia W, Chou Y, Huang ZY et al. LCI ESI-MS method for the determination of trimetazidine in human plasma: application to a bioequivalence study on Chinese volunteers. J Pharm Biomed Anal 2007; 43: 1804-7
• 12 Ullah MA, Azad MAK, Sultana R, Akbor MM, Hasan A, Latif AHMM et al. bioequivalence evaluation of two capsule formulations of amoxicillin in healthy adult male Bangladeshi volunteers: a single-dose, randomized, open-label, two-period crossover study. Curr Ther Res Clin Exp 2008; 69 (6) 504-13
• 13 European Agency for the Evaluation of Medicinal Products, International Conference on Harmonization - World Health Organization. Guideline for Good Clinical Practice. ICH topic E6 (Rl). July, 2002. Available from: http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf Accessed June, 20, 2010
• 14 World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59^th WMA General Assembly, Seoul, South Korea, October 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html Accessed June 20, 2010
• 15 FDA Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Rock-ville, MD: Office of Generic Drugs, Division of Bioequivalence, US Food and Drug Administration; 2003
• 16 Jones B, Kenward GM. Design and analysis of cross-over trials. 2nd ed. London: Chapman and Hall/CRC; 2003
• 17 Portoles A, Terleira A, Almeida S, García-Arenillas M, Caturla MC, Filipe A et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): a randomized, two-way, open label, crossover study in healthy volunteers. Curr Ther Res Clin Exp 2004; 65: 34-46